SYRE Projected Dividend Yield
Spyre Therapeutics Inc ( NASDAQ : SYRE )Aeglea BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biotechnology company developing human enzyme therapeutics for people with rare metabolic diseases. Co.'s development programs include: Pegzilarginase in Arginase 1 Deficiency, which is a recombinant human Arginase 1 that enzymatically degrades the amino acid arginine and improves the stability and arginine-degrading activity of the enzyme in human plasma; and AGLE-177 in Homocystinuria, which is a PEGylated, or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine. Co.'s preclinical pipeline includes cystinuria program to reduce plasma cystine and cysteine levels. 20 YEAR PERFORMANCE RESULTS |
SYRE Dividend History Detail SYRE Dividend News SYRE Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |